Anakinra is  recombinant interleukin (IL)-1 receptor antagonist.  A new study published in  Arthritis & Rheumatism online has found that anakinra is safe and effective for severe Muckle-Wells syndrome.

The researchers investigated the efficacy of anakinra in 12 patients with severe Muckle Wells syndrome. Seven patients were adults and five were children.

All constitutional symptoms resolved by 2 weeks, and there was near complete resolution of musculoskeletal manifestations and significant improvement in ocular symptoms and skin manifestations. [Read more...]